Product Information
OXYBUTYNIN CL ER 5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0817 per EA under NDC 64980020905. Its NADAC has been published 183 times since Feb 22, 2023.
FDA first approved this application on May 27, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Oxybutynin Chloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980020905
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA206121FDA Approved
5/27/2016
TE Code
AB
On Market Since
9/27/2016
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN CL ER 5 MG TABLET has been published 183 times since Feb 22, 2023, and over the history we have for it it has declined 26.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0817 per EA |
|---|---|
| All-time high | $0.1157 (Sep 13, 2023) |
| All-time low | $0.0765 (Nov 20, 2024) |
| 52-week high | $0.0990 |
| 52-week low | $0.0817 |
| Median price | $0.0972 |
| Average price | $0.0975 |
| Largest weekly change | +35.7% (Jun 19, 2024) |
| Weeks tracked | 183 |
| Tracking since | Feb 22, 2023 |
Generic Alternatives
The matcher finds 14 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 42% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of OXYBUTYNIN CL ER 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN CL ER 5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0817 per EA (NDC 64980020905), effective Aug 19, 2026.
How has the price of OXYBUTYNIN CL ER 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has declined 26.8%. It has been tracked across 183 weekly CMS publications since Feb 22, 2023.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN CL ER 5 MG TABLET?
Since Feb 22, 2023, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has ranged from a low of $0.0765 (Nov 20, 2024) to a high of $0.1157 (Sep 13, 2023), with a median of $0.0972 per EA.
Are there cheaper alternatives to OXYBUTYNIN CL ER 5 MG TABLET?
Yes. 14 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXYBUTYNIN 5 MG TABLET, is $0.0473 per EA — about 42% below OXYBUTYNIN CL ER 5 MG TABLET.
Who manufactures OXYBUTYNIN CL ER 5 MG TABLET?
OXYBUTYNIN CL ER 5 MG TABLET (NDC 64980020905) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.